The new data presented by Novartis at ECTRIMS 2022 highlighted the safety and efficacy of Kesimpta and supported its use as an early intervention treatment option, as well as demonstrating high ...

Novartis has secured backing from NICE for its relapsing multiple sclerosis (RMS) therapy Kesimpta in the UK, just two weeks after the drug was approved by the national drugs regulator.

GlobalData spotlighted Roche’s Ocrevus and Novartis’ Kesimpta as leaders in the space; Ocrevus, in particular, is expected to reel in more than $8 billion in sales this year, representing ...

We expect leading efficacy from multiple sclerosis drug Kesimpta, and cancer drugs Kisqali and Pluvicto will support significant growth for these top Novartis drugs. We expect additional growth ...

Novartis’ efforts to strengthen its wide portfolio by developing breakthrough treatments have made it even more formidable in this space. Kesimpta, Pluvicto, Scemblix, Kisqali, Leqvio and ...

Novartis hat auch in der Schweiz die Zulassung für das Krebsmedikament Kisqali erhalten. So habe Swissmedic das Mittel zur ...

Der Schweizer Pharmakonzern verzeichnet leichte Kursgewinne und erhöht seine Dividende zum 28. Mal in Folge, während Experten zurückhaltende Kursziele prognostizieren.

Novartis’ efforts to strengthen its wide portfolio by developing breakthrough treatments have made it even more formidable in this space. Kesimpta, Pluvicto, Scemblix, Kisqali, Leqvio and ...

Der Pharmakonzern Novartis stellt an einem Branchenkongress neue Daten zum Medikament Kesimpta gegen Multiple Sklerose vor.